Results of phase 3b ENSURE-AF study investigating edoxaban in AF patients undergoing cardioversion to be presented at ESC

Andreas Goette
Andreas Goette

Daiichi Sankyo has announced it will present the first results from ENSURE-AF, the largest prospective randomised clinical trial to date evaluating a non-vitamin K antagonist oral anticoagulant (edoxaban) compared to a current standard of care in patients with non-valvular atrial fibrillation undergoing electrical cardioversion.

The trial, which included nearly 2,200 patients from 19 countries, will be presented by Andreas Goette, (St Vincenz-Hospital, Paderborn, Germany) in a late-breaking clinical trial presentation on Tuesday 30 August.

In addition, five analyses from the global phase 3 ENGAGE AF-TIMI 48 study of edoxaban (known by the brand name Lixiana outside the USA and Savaysa in the USA) will be presented, including clinical outcomes associated with dose interruption in patients with non-valvular atrial fibrillation compared to warfarin, relationship between body mass index and clinical outcomes, and a novel risk prediction score for net clinical outcome assessment.

Furthermore, six analyses from the PREFER in atrial fibrillation (AF) registry and one analysis from the PREFER in venous thromboembolism (VTE) registry will be presented, with new insights into the use of non-vitamin K antagonist oral anticoagulant therapy, including prescribing patterns and trends in acute and long-term management of patients with AF and VTE.